Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;26(5):e101-e112.
doi: 10.1016/j.bbmt.2020.01.004. Epub 2020 Jan 11.

Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults

Erin Gatza  1 , Pavan Reddy  2 , Sung Won Choi  3
Affiliations
Review

Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults

Erin Gatza et al. Biol Blood Marrow Transplant. 2020 May.

Abstract

Acute graft-versus-host disease (GVHD) continues to be a major cause of morbidity and mortality after allogeneic hematopoietic cell transplant (HCT) in pediatric patients (ie, children and adolescent and young adults) and limits broader application of the therapy. Pediatric HCT patients have faced major obstacles to access clinical trials that test new agents for GVHD prevention and treatment. According to a recent search, only 6 clinical trials of interventions for prevention or treatment of acute GVHD were conducted specifically in pediatric patients in the United States over the past decade, with 8 internationally. In this review, we summarize the studies that were performed and specifically enrolled and reported on pediatric patients after allogeneic HCT and provide a listing of studies currently under way.

Keywords: Acute GVHD; Clinical trials; HCT; Pediatrics.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure Statement: The authors have no financial interests to disclose.

DISCLOSURE OF CONFLICTS OF INTEREST

The authors have no conflicts-of-interests to disclose.

References

    1. D’Souza A, Lee S, Zhu X, et al. Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417–21. - PMC - PubMed
    1. Khandelwal P, Millard HR, Thiel E, et al. Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Biol Blood Marrow Transplant. 2017;23(8):1342–9. - PMC - PubMed
    1. Carpenter PA, Macmillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am. 2010;57(1):273–95. - PMC - PubMed
    1. Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008;112(4):1539–42. - PMC - PubMed
    1. Doring M, Cabanillas Stanchi KM, Mezger M, et al. Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation. BMC Cancer. 2015;15:607. - PMC - PubMed